FKBP5 blockade may provide a new horizon for the treatment of stress-associated disorders: An in-silico study.

ABSTRACT:

Objective

We searched for, from the FDA (Food and Drug Administration-USA)-approved drugs, inhibitors of FKBP5 with tolerable adverse effect profiles (eg, mild headache, sedation, etc.) and with the ability to cross the blood brain barrier (BBB), using bio-informatics tools (in-silico). This may pave the road for designing clinical trials of such drugs in patients with functional seizures (FS) and other stress-associated disorders.

Methods

Several databases were used to find all the approved drugs that potentially have interactions with FKBP51 protein [ie, CTD gene-chemical interaction section of FKBP51 protein of Harmonizome of Mayaanlab, DrugCenteral database, PDID (Protein Drug Interaction Database), DGIdb (the Drug Gene Interaction database)]. Other databases were also s

SUBMITTER: Asadi-Pooya AA 

PROVIDER: S-EPMC10235572 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature